中国防痨杂志 ›› 2023, Vol. 45 ›› Issue (6): 607-612.doi: 10.19982/j.issn.1000-6621.20230018
收稿日期:
2023-03-01
出版日期:
2023-06-10
发布日期:
2023-06-06
通信作者:
陈伟
E-mail:chenwei@chinacdc.cn
基金资助:
Wang Boning, Li Tao, Chen Wei()
Received:
2023-03-01
Online:
2023-06-10
Published:
2023-06-06
Contact:
Chen Wei
E-mail:chenwei@chinacdc.cn
Supported by:
摘要:
尽管全球结核病疫情呈现下降趋势,耐药结核病的经济负担却日益加重。究其原因,耐药结核病的治疗药物昂贵,病程迁延不愈,治疗不良反应严重。作者对耐药结核病经济负担进行综述,揭示目前耐药结核病经济负担的研究现状及其影响因素,以期为后续研究和医保政策制订提供参考。
中图分类号:
王泊宁, 李涛, 陈伟. 耐药结核病经济负担研究进展[J]. 中国防痨杂志, 2023, 45(6): 607-612. doi: 10.19982/j.issn.1000-6621.20230018
Wang Boning, Li Tao, Chen Wei. Progress on economic burden of patients with drug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2023, 45(6): 607-612. doi: 10.19982/j.issn.1000-6621.20230018
[1] |
王仲元. 耐药结核病的研究进展. 传染病信息, 2018, 31(1):19-23. doi:10.3969/j.issn.1007-8134.2018.01.005.
doi: 10.3969/j.issn.1007-8134.2018.01.005 |
[2] | World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022. |
[3] |
Tanimura T, Jaramillo E, Weil D, et al. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J, 2014, 43(6):1763-1775. doi:10.1183/09031936.00193413.
doi: 10.1183/09031936.00193413 pmid: 24525439 |
[4] | 陈文. 卫生经济学. 4版. 北京: 人民卫生出版社, 2017. |
[5] |
Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol, 2014, 20(4):327-337. doi:10.3350/cmh.2014.20.4.327.
doi: 10.3350/cmh.2014.20.4.327 pmid: 25548737 |
[6] |
何敏媚, 何闽江, 崔斌. 疾病经济负担研究进展. 中国老年学杂志, 2010, 30(18):2700-2702. doi:10.3969/j.issn.1005-9202.2010.18.071.
doi: 10.3969/j.issn.1005-9202.2010.18.071 |
[7] |
Sun X, Jackson S, Carmichael G, et al. Catastrophic medical payment and financial protection in rural China: evidence from the New Cooperative Medical Scheme in Shandong Province. Health Economics, 2009, 18(1): 103-119. doi:10.1002/hec.1346.
doi: 10.1002/hec.1346 pmid: 18283715 |
[8] |
Mullerpattan JB, Udwadia ZZ, Banka RA, et al. Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India. Indian J Tuberc, 2019, 66(1):87-91. doi:10.1016/j.ijtb.2018.04.011.
doi: 10.1016/j.ijtb.2018.04.011 URL |
[9] | Wingfield T. World Health Organisation Tuberculosis Patient Costs Surveys: a handbook. Geneva: World Health Organization, 2017. |
[10] |
杨天池, 陈琴, 陈同, 等. 宁波市利福平耐药肺结核患者家庭灾难性医疗支出及其影响因素分析. 中国防痨杂志, 2019, 41(11):1191-1196. doi:10.3969/j.issn.1000-6621.2019.11.009.
doi: 10.3969/j.issn.1000-6621.2019.11.009 |
[11] |
朱磷扬, 杨皓舒, 仲崇桥, 等. 连云港市耐利福平结核病人主要危险因素及经济负担. 江苏预防医学, 2016, 27(3):268-270. doi:10.13668/j.issn.1006-9070.2016.03.04.
doi: 10.13668/j.issn.1006-9070.2016.03.04 |
[12] |
王倩, 张修磊, 阴佳. 山东省耐多药肺结核患者医疗费用灾难性支出分析研究. 河南预防医学杂志, 2020, 31(12):918-920. doi:10.13515/j.cnki.hnjpm.1006-8414.2020.12.013.
doi: 10.13515/j.cnki.hnjpm.1006-8414.2020.12.013 |
[13] | 张广川. 广州市耐多药肺结核经济负担及影响因素分析. 广州:广东药科大学, 2021. |
[14] |
Nam VX, Nhung NV, Hoa NB, et al. Economic burden of multidrug-resistant tuberculosis: a multicenter study across Vietnamese regions. Int J Tuberc Lung Dis, 2018, 22(8):912-917. doi:10.5588/ijtld.18.0039.
doi: 10.5588/ijtld.18.0039 pmid: 29991401 |
[15] |
Florentino JL, Arao RML, Garfin AMC, et al. Expansion of social protection is necessary towards zero catastrophic costs due to TB: The first national TB patient cost survey in the Philippines. PLoS One, 2022, 17(2):e264689. doi:10.1371/journal.pone.0264689.
doi: 10.1371/journal.pone.0264689 |
[16] |
Lee S, Kim MJ, Lee SH, et al. Comparison of Disability-Adjusted Life Years (DALYs) and Economic Burden on People With Drug-Susceptible Tuberculosis and Multidrug-Resistant Tuberculosis in Korea. Front Public Health, 2022, 10:848370. doi:10.3389/fpubh.2022.848370.
doi: 10.3389/fpubh.2022.848370 |
[17] |
Fitzpatrick C, Floyd K. A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis. Pharmacoeconomics, 2012, 30(1):63-80. doi:10.2165/11595340-000000000-00000.
doi: 10.2165/11595340-000000000-00000 pmid: 22070215 |
[18] |
Rouzier VA, Oxlade O, Verduga R, et al. Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador. Int J Tuberc Lung Dis, 2010, 14(10):1316-1322.
pmid: 20843424 |
[19] |
van den Hof S, Collins D, Hafidz F, et al. The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan. BMC Infect Dis, 2016, 16(1):470. doi:10.1186/s12879-016-1802-x.
doi: 10.1186/s12879-016-1802-x |
[20] |
Mullerpattan JB, Udwadia ZZ, Banka RA, et al. Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India. Indian J Tuberc, 2019, 66(1):87-91. doi:10.1016/j.ijtb.2018.04.011.
doi: 10.1016/j.ijtb.2018.04.011 URL |
[21] |
Pedrazzoli D, Siroka A, Boccia D, et al. How affordable is TB care? Findings from a nationwideTB patient cost survey in Ghana. Trop Med Int Health, 2018, 23(8):870-878. doi:10.1111/tmi.13085.
doi: 10.1111/tmi.13085 pmid: 29851223 |
[22] |
Nhung NV, Hoa NB, Anh NT, et al. Measuring catastrophic costs due to tuberculosis in Viet Nam. Int J Tuberc Lung Dis, 2018, 22(9):983-990. doi:10.5588/ijtld.17.0859.
doi: 10.5588/ijtld.17.0859 pmid: 30092862 |
[23] |
Timire C, Ngwenya M, Chirenda J, et al. Catastrophic costs among tuberculosis-affected households in Zimbabwe: A national health facility-based survey. Trop Med Int Health, 2021, 26(10):1248-1255. doi:10.1111/tmi.13647.
doi: 10.1111/tmi.13647 URL |
[24] |
Berhanu RH, Schnippel K, Kularatne R, et al. Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia?. Int J Tuberc Lung Dis, 2019, 23(3):358-362. doi:10.5588/ijtld.17.0837.
doi: 10.5588/ijtld.16.0837 pmid: 30940300 |
[25] |
Gomez MA, Millet JP, Maldonado J, et al. The costs of MDR/XDR tuberculosis in Barcelona (Spain): Cases treated with DOTs/DOT plus in a specialized centre. Eur Respir J, 2016,48. doi:10.1183/13993003.congress-2016.PA2718.
doi: 10.1183/13993003.congress-2016.PA2718 |
[26] |
Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J, 2014, 43(2):554-565. doi:10.1183/09031936.00079413.
doi: 10.1183/09031936.00079413 pmid: 23949960 |
[27] |
Feuth T, Patovirta R, Grierson S, et al. Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines. Int J Tuberc Lung Dis, 2021, 25(7):554-559. doi:10.5588/ijtld.20.0892.
doi: 10.5588/ijtld.20.0892 pmid: 34183100 |
[28] |
Lee S, Kim MJ, Lee SH, et al. Comparison of Disability-Adjusted Life Years (DALYs) and Economic Burden on People With Drug-Susceptible Tuberculosis and Multidrug-Resistant Tuberculosis in Korea. Front Public Health, 2022, 10:848370. doi:10.3389/fpubh.2022.848370.
doi: 10.3389/fpubh.2022.848370 |
[29] | 陈丽金, 周颖, 钟云, 等. 广东省耐多药结核病患者疾病经济负担研究. 中国卫生经济, 2021, 40(3):72-75. |
[30] | 张加胜. 耐多药肺结核患者的医疗费用、经济负担及补偿现状——38例患者个案研究. 济南:山东大学, 2011. |
[31] | 热孜亚木. 2013—2017年新疆某专科医院耐药肺结核患者医疗费用变化情况及影响因素研究. 乌鲁木齐:新疆医科大学, 2018. |
[32] | 闫赟. 中国5城市耐多药肺结核患者诊治及管理现状研究. 济南:山东大学, 2010. |
[33] |
Muttamba W, Tumwebaze R, Mugenyi L, et al. Households experiencing catastrophic costs due to tuberculosis in Uganda: magnitude and cost drivers. BMC Public Health, 2020, 20(1):1409. doi:10.1186/s12889-020-09524-5.
doi: 10.1186/s12889-020-09524-5 pmid: 32938411 |
[34] |
Kilale AM, Pantoja A, Jani B, et al. Economic burden of tuberculosis in Tanzania: a national survey of costs faced by tuberculosis-affected households. BMC Public Health, 2022, 22(1):600. doi:10.1186/s12889-022-12987-3.
doi: 10.1186/s12889-022-12987-3 pmid: 35351063 |
[35] |
Grobler L, Nagpal S, Sudarsanam TD, et al. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev, 2016, 2016(6): CD006086. doi:10.1002/14651858.CD006086.pub4.
doi: 10.1002/14651858.CD006086.pub4 |
[36] |
Wang Y, McNeil EB, Huang Z, et al. Household financial burden among multidrug-resistant tuberculosis patients in Guizhou province, China. Medicine (Baltimore), 2020, 99(28):e21023. doi:10.1097/MD.0000000000021023.
doi: 10.1097/MD.0000000000021023 |
[37] |
申丽君, 王艺曈, 李雪, 等. 基于疗程费用测算耐药结核病患者药物负担. 中国防痨杂志, 2019, 41(9):962-967. doi:10.3969/j.issn.1000-6621.2019.09.010.
doi: 10.3969/j.issn.1000-6621.2019.09.010 |
[38] |
叶家利, 吴惠忠, 邹霞, 等. 162例耐多药结核病患者经济负担影响因素分析. 热带医学杂志, 2020, 20(4):441-445. doi:10.3969/j.issn.1672-3619.2020.04.005.
doi: 10.3969/j.issn.1672-3619.2020.04.005 |
[39] |
孙强, 闫赟, 边学峰, 等. 耐多药肺结核患者医疗费用及经济负担分析. 中国卫生经济, 2011, 30(1):33-35. doi:10.3969/j.issn.1003-0743.2011.01.012.
doi: 10.3969/j.issn.1003-0743.2011.01.012 |
[40] |
Wang Y, Chen H, Huang Z, et al. Drug Non-Adherence And Reasons Among Multidrug-Resistant Tuberculosis Patients In Guizhou, China: A Cross-Sectional Study. Patient Prefer Adherence, 2019, 13:1641-1653. doi:10.2147/PPA.S219920.
doi: 10.2147/PPA.S219920 URL |
[1] | 中国人民解放军总医院第八医学中心结核病医学部, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会. 浅表淋巴结结核的诊断与治疗专家共识[J]. 中国防痨杂志, 2023, 45(6): 531-542. |
[2] | 中国人民解放军总医院第八医学中心结核病医学部, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会. 核酸基质辅助激光解吸电离飞行时间质谱技术在结核病和非结核分枝杆菌病诊断中的临床应用专家共识[J]. 中国防痨杂志, 2023, 45(6): 543-558. |
[3] | 宋媛媛, 夏辉. 全国结核病实验室网络室间质量评价满意度调查[J]. 中国防痨杂志, 2023, 45(6): 559-565. |
[4] | 何萍, 王怡婷, 宋泽萱, 夏辉, 王胜芬, 贺文从, 郑扬, 赵雁林. 结核分枝杆菌Rv2333c在巨噬细胞内功能的初步研究[J]. 中国防痨杂志, 2023, 45(6): 566-574. |
[5] | 尚耀民, 周晓蕾, 薛运玲, 冷霞. 微卡与维生素D联合应用对初治涂阳肺结核CD4+ T细胞亚群平衡的影响[J]. 中国防痨杂志, 2023, 45(6): 575-582. |
[6] | 王嫩寒, 田丽丽, 陈双双, 赵琰枫, 樊瑞芳, 陈昊, 任怡宣, 张洁, 易俊莉, 杨新宇, 于兰, 丁北川, 李传友, 代小伟. 荧光PCR探针熔解曲线技术检测痰标本结核分枝杆菌利福平耐药性的研究[J]. 中国防痨杂志, 2023, 45(6): 583-588. |
[7] | 张治国, 尚媛媛, 张旭霞, 刘荣梅, 马丽萍, 秦林, 孔忠顺, 任卫聪. CRISPR-Cas13a检测在肺结核诊断中的价值[J]. 中国防痨杂志, 2023, 45(6): 589-593. |
[8] | 杨超, 王晶, 唐桂林, 耿洋. 2012—2021年北京市通州区流动人口肺结核流行特征及治疗转归分析[J]. 中国防痨杂志, 2023, 45(6): 594-600. |
[9] | 彭孝旺, 樊晓蕾, 向阳, 买吾拉江·依马木, 胡鹏远, 王艳杰, 腾子豪. 新疆维吾尔自治区喀什地区活动性肺结核密切接触者发病及影响因素分析[J]. 中国防痨杂志, 2023, 45(6): 601-606. |
[10] | 董静, 史雨婷, 潘丽萍, 张宗德. 长链非编码RNA抗结核分枝杆菌感染功能的研究进展[J]. 中国防痨杂志, 2023, 45(6): 613-619. |
[11] | 温立旻, 侯代伦. 肺结核合并肺癌影像学评估方法现状及进展[J]. 中国防痨杂志, 2023, 45(6): 620-624. |
[12] | 薛人伟, 蒋慧芳, 陶叠宏, 蒋玉霞, 吴海英. 多发性骨髓瘤CAR-T细胞治疗后并发肺结核一例[J]. 中国防痨杂志, 2023, 45(6): 625-627. |
[13] | 廖艺璇, 方创森, 李燕明. 加强结核病非定点医疗机构能力建设提高结核病诊断水平[J]. 中国防痨杂志, 2023, 45(5): 437-441. |
[14] | 王大宽, 张彬, 刘自森, 段伟焘, 高磊. 基层结核病预防性治疗门诊建设的探索与展望[J]. 中国防痨杂志, 2023, 45(5): 442-445. |
[15] | 李姗姗, 王玉峰, 舒薇, 逄宇. 结核病实验室诊断技术研发新进展[J]. 中国防痨杂志, 2023, 45(5): 446-453. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||